MYGN vs. CLDX, NTLA, NEOG, QDEL, LNTH, CPRX, INBX, HRMY, FUSN, and EVO
Should you be buying Myriad Genetics stock or one of its competitors? The main competitors of Myriad Genetics include Celldex Therapeutics (CLDX), Intellia Therapeutics (NTLA), Neogen (NEOG), QuidelOrtho (QDEL), Lantheus (LNTH), Catalyst Pharmaceuticals (CPRX), Inhibrx (INBX), Harmony Biosciences (HRMY), Fusion Pharmaceuticals (FUSN), and Evotec (EVO). These companies are all part of the "medical" sector.
Celldex Therapeutics (NASDAQ:CLDX) and Myriad Genetics (NASDAQ:MYGN) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, profitability and community ranking.
Celldex Therapeutics received 134 more outperform votes than Myriad Genetics when rated by MarketBeat users. Likewise, 74.88% of users gave Celldex Therapeutics an outperform vote while only 53.57% of users gave Myriad Genetics an outperform vote.
Celldex Therapeutics currently has a consensus price target of $66.00, suggesting a potential upside of 63.81%. Myriad Genetics has a consensus price target of $24.86, suggesting a potential downside of 2.60%. Given Myriad Genetics' stronger consensus rating and higher probable upside, research analysts plainly believe Celldex Therapeutics is more favorable than Myriad Genetics.
In the previous week, Myriad Genetics had 9 more articles in the media than Celldex Therapeutics. MarketBeat recorded 29 mentions for Myriad Genetics and 20 mentions for Celldex Therapeutics. Myriad Genetics' average media sentiment score of 0.60 beat Celldex Therapeutics' score of 0.38 indicating that Celldex Therapeutics is being referred to more favorably in the media.
Myriad Genetics has a net margin of -34.96% compared to Myriad Genetics' net margin of -2,054.46%. Celldex Therapeutics' return on equity of -8.03% beat Myriad Genetics' return on equity.
Celldex Therapeutics has a beta of 1.6, suggesting that its stock price is 60% more volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 1.96, suggesting that its stock price is 96% more volatile than the S&P 500.
99.0% of Myriad Genetics shares are held by institutional investors. 3.7% of Celldex Therapeutics shares are held by insiders. Comparatively, 2.0% of Myriad Genetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Celldex Therapeutics has higher earnings, but lower revenue than Myriad Genetics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.
Summary
Celldex Therapeutics and Myriad Genetics tied by winning 9 of the 18 factors compared between the two stocks.
Get Myriad Genetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MYGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Myriad Genetics Competitors List
Related Companies and Tools
